As previously mentioned, a major pitfall in using glycolipid antigens, specifically αGC, as adjuvants in cancer immunotherapy is the induction of iNKT cell anergy, as defined by reduced IFN-γ secretion upon secondary exposure. The gene discussed is IFNG; the disease is cancer.